MFN2 and obesity disorder: The dihydroorotate dehydrogenase inhibitor leflunomide triggers transcriptional up‐regulation of the mitochondrial fusion factors MFN1 and MFN2 (Miret‐Casals et al, 2018) and has been tested in murine obesity models.